INFRASTRUCTURE

Neutrino probe is key priority for US physics

Nuclear-science wish list also includes particle collider.

BY DAVIDE CASTELVECCHI

Two large science experiments head a wish list drawn up by US nuclear physicists for the next decade: a quest to uncover the nature of neutrinos and a particle collider to study the forces that bind quarks.

The big-ticket items, each of which would cost hundreds of millions of dollars, are among the top priorities highlighted by the Nuclear Science Advisory Committee (NSAC) on 15 October. Every 5–7 years, this panel of high-level nuclear physicists presents a long-term plan to the US Department of Energy and National Science Foundation, after consulting the US nuclear-physics community.

The agenda assumes that US funding for nuclear science will increase by 1.6% per year above inflation — a realistic scenario, says NSAC chair Donald Geesaman, a physicist at Argonne National Laboratory in Illinois. “We have exciting science to do, and we are not asking for large increases,” he says.

The neutrino experiment, construction of which could begin by the end of the decade, would search for a theorized rare form of radioactive decay in which two identical neutrinos annihilate one another — an event that would imply that neutrinos are their own anti-particles. It could provide a way to measure the tiny mass of neutrinos and help to explain why the Universe has lots of matter but almost no antimatter.

Experiments around the world using materials such as liquid xenon have failed to detect the event, known as neutrinoless double β decay. But the NSAC report says that an experiment using a tonne or more of material — about ten times more than any previous attempt — could either find or rule out the phenomenon.

Another priority, on which *Nature* reported in May (see *Nature* 521, 272; 2015), is a particle accelerator that would collide electrons with protons or heavy ions to investigate gluons, which carry the force that binds quarks. But construction would have to wait until the 2020s because NSAC’s top priority is to complete and maintain existing facilities, such as the Relativistic Heavy Ion Collider (RHIC) at Brookhaven National Laboratory in Upton, New York. RHIC faced closure two years ago, but an improved budgetary position means it can now be sustained into the next decade. ■

a new type of career path in the process. Although academic researchers from fields such as computer science and engineering have led innovative Google projects (such as the Internet-connected eyewear known as Glass), Google and other technology companies are increasingly recruiting life scientists as Silicon Valley broadens its reach into health care. “I have a feeling we’re going to see a lot more recruitment of leading lights,” says Eric Topol, director of the Scripps Translational Science Institute in La Jolla, California.

In September, Thomas Insel, director of the US National Institute of Mental Health in Bethesda, Maryland, announced that he would soon be joining Google’s life-sciences company to help develop ways to apply technology in mental health. And last year, molecular biologist Cynthia Kenyon, a leader in ageing research at the University of California, San Francisco, joined the Google-backed biotech company Calico in San Francisco, California.

Cardiologist Euan Ashley of Stanford University, which sits in the thick of Silicon Valley, says that academic data scientists are constantly tempted by the companies that await them just off campus. “They’re being continuously recruited away,” he says. “We’re in competition with Google and other tech companies, and generally they can pay a lot more than Stanford can.”

But money is not the only lure. Silicon Valley offers strong technology resources that are hard to access in academia, Topol says, as well as the opportunity to pursue goals that are difficult to reach for in academia, where scientists are not typically rewarded for pursuing real-world applications. “The resources are exponentially greater than what you can get through academic circles. And the metrics are different: instead of publications, it’s just, ‘Get stuff done,’” he says.

Getting stuff done was foremost in the mind of electrical engineer Brian Otis when he left his tenured position at the University of Washington in Seattle in 2012 to work for Google. He went there to work on a ‘smart’ contact lens for people with diabetes that measures the level of glucose in tears. When the project began, it faced two big questions: first, could the electronics needed to make a functional wireless glucose sensor be embedded in a wearable contact lens? And second, would it provide the relevant measurements of glucose levels? The motivation and means to answer those unknowns was a powerful incentive, Otis says. He recalls thinking: “If I come into Google life with these questions, I have the entire runway and resources to answer these two questions.”

The project was successful; drug giant Novartis licensed the contact-lens technology last year and Otis is now director of the Google life-sciences team’s hardware and medical-device development. “To go all the way from

foundational first principles to execution of vision was the initial draw, and that’s what has continued to keep me here,” he says.

Apple, too, has entered the health-care game. In March, it debuted ResearchKit, a framework through which researchers can write apps that collect data from patients’ mobile phones. And in April, IBM launched IBM Watson Health and the Watson Health Cloud, services that use the company’s cognitive computing technology to process large amounts of health data from diverse sources. The service could help physicians to manage patients’ health by streaming data from personal electronic devices, or enable drug companies to manage clinical trials more efficiently with cloud computing. Intel, meanwhile, is developing cloud-computing services to provide more personalized cancer care; and Facebook, Microsoft and Amazon are also getting involved.

But Google’s approach sets it apart: the company expends more resources on potential

“The resources are exponentially greater than what you can get through academic circles.”

health applications and is exploring in more directions than others are. Observers estimate that Google puts more than a billion dollars per year into life-sciences

research, although the company says that it does not break down its spending in that way.

Google’s life-sciences team is working on a range of projects that involve developing new ways of monitoring health. As well as the smart contact-lens project, there is the Baseline Study, which aims to collect large amounts of data about people to better quantify health and disease, with the goal of earlier and more-effective preventive care. The company also funds a huge array of external collaborations with academics. Google Genomics, for instance, is studying the application of cloud computing to genomics, and Calico has signed a slew of collaborations with companies and academic institutes.

“They’re reaching out to academia in a way that biotechnology companies often don’t,” says cell and molecular biologist Judith Campisi of the Buck Institute for Research on Aging in Novato, California. That enables scientists to collaborate with Google instead of joining it wholesale.

“For some academics, joining a technology company would be an exciting new opportunity,” says physician Steven Hyman of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. But it is “not a likely destination for those interested in mitigating risk,” he says. “After all, the life-science goals of the Googles, Apples and Microsofts of the world are likely to change in the near term as the companies explore an area that is new to them.” ■